Spotlight On... Sanofi commits to developing Zika vax while other big players will evaluate; Perrigo expands recall of children's cold med; AmerisourceBergen reports for Q4 2015; Porton adds to U.K. manufacturing; and more...

Sanofi ($SNY) says it intends to apply its decades of vaccine development work and manufacturing expertise in dengue fever to try to create a vaccine for Zika virus, the mosquito-borne disease that the World Health Organization this week called a global health emergency. The other large vaccine makers have committed to at least evaluating whether they might be able to respond. GlaxoSmithKline ($GSK), Pfizer ($PFE), Merck ($MRK), Johnson & Johnson ($JNJ) and Takeda all followed Sanofi's announcement by saying that they'd look into their existing vaccines and technologies for the potential to create a Zika vaccine. Sanofi and GSK have expertise with vaccines for mosquito-borne diseases. GSK has an approved jab for malaria and Sanofi is rolling out its vaccine for dengue fever. Story

> Perrigo ($PRGO), already recalling grape-flavored versions of its store brand for the popular cold med Mucinex for children, added three lots of the cherry-flavored version to its national recall. Report

> Drug distributor AmerisourceBergen ($ABC) cited its acquisition of compounder PharMEDium as providing some lift to its Q4 2015 earnings during a challenging period. Report

> Porton Biopharma has opened a new manufacturing facility in Porton Down in Wiltshire, U.K., allowing it to increase production of Erwinase, a treatment for a rare form of leukemia in children. Release

> Two weeks after it was approved by the European Commission, Norway became the first overseas country to approve the Enbrel biosimilar Benepali made by Samsung Bioepis. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.